Home › Castration-Resistant Prostatic Cancer › Virginia
Castration-Resistant Prostatic Cancer clinical trials in Virginia
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Virginia.
Cities in Virginia
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
- Blue Ridge Cancer Care, Roanoke
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Investigational Site number: 404, Fairfax
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.